Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674647 · ClinicalTrials.gov registry record · Phase 3
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,504
- Enrollment target
NCT01674647 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,504 participants.
The verdict
NCT01674647, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,504 participants
- Enrollment target
Study Summary
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Vitamin K antagonist (VKA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674647
The ClinicalTrials.gov registry entry for NCT01674647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT01674647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674647 about?
NCT01674647 is a clinical study titled "Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion". A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure com...
What is the current status of trial NCT01674647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,504 participants. The study started on 2012-10. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01674647?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Vitamin K antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT01674647?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.